Document Detail

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.
MedLine Citation:
PMID:  21566669     Owner:  NLM     Status:  MEDLINE    
Approximately one third of patients with advanced human epidermal growth factor receptor 2 (HER-2)/neu-positive breast cancer respond to trastuzumab monotherapy, a humanized anti-HER-2/neu antibody. However, de novo and acquired antibody resistance is one of the major limitations of trastuzumab therapy warranting the search for other therapeutic strategies. One of the most remarkable features of adenovirus (AdV)-based vaccine is its ability to induce exceptionally high and sustained frequencies of transgene product-specific CD8(+) T-cell responses. In this study, we constructed two recombinant AdVs (AdV(OVA) and AdV(HER-2)) expressing ovalbumin (OVA) and HER-2/neu, and assessed AdV-induced antigen-specific cellular immune responses and preventive/therapeutic antitumor immunity. We demonstrate that AdV(OVA) stimulates efficient OVA-specific CD8(+) cytotoxic T lymphocyte (CTL) and natural killer responses, leading to preventive long-term immunity against OVA-expressing BL6-10ova melanoma in wild-type C56BL/6 mice. We further demonstrate that AdV(HER-2) stimulates HER-2/neu-specific CD8(+) CTL responses, leading to a significant reduction in breast carcinogenesis in transgenic FVBneuN mice (P<0.05), but has little therapeutic effect on pre-existing Tg1-1 tumor even at early stage (15 mm(3)). In contrast, the anti-HER-2/neu antibody therapy is capable of completely inhibiting Tg1-1 tumor growth at early stage, but fails to eradicate well-established Tg1-1 breast tumor (100 mm(3)). Interestingly, a combinatorial immunotherapy of anti-HER-2/neu antibody with AdV(HER-2) vaccine was capable of curing 4 of 10 studied mice bearing well-established Tg1-1 breast tumors and significantly delaying in death of the remaining six tumor-bearing mice (P<0.05). Taken together, our results suggest an adjuvant effect of AdV(HER-2) on anti-HER-2/neu antibody therapy for well-established breast tumor in transgenic FVBneuN mice, and this combinatorial immunotherapy of trastuzumab with AdV(HER-2) vaccine may be used as a new therapeutic strategy for treatment of advanced HER-2/neu-positive breast cancer.
Y Chen; Y Xie; T Chan; A Sami; S Ahmed; Q Liu; J Xiang
Related Documents :
23085629 - Characterization of an early passage merkel cell polyomavirus-positive merkel cell carc...
24810989 - Yap1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.
22949379 - A multifactorial likelihood model for mmr gene variant classification incorporating pro...
25012819 - Dissecting tumor heterogeneity in flies: genetic basis of interclonal oncogenic coopera...
23717449 - Elevated maspin expression is associated with better overall survival in esophageal squ...
24511119 - Galectin-1 upregulates cxcr4 to promote tumor progression and poor outcome in kidney ca...
20706639 - High-speed burring with and without the use of surgical adjuvants in the intralesional ...
7525669 - Qbend/10 (anti-cd34 antibody) in external root sheath cells and follicular tumors.
12973089 - Intraoperative liver ultrasound: the chinese experience.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-05-13
Journal Detail:
Title:  Cancer gene therapy     Volume:  18     ISSN:  1476-5500     ISO Abbreviation:  Cancer Gene Ther.     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-17     Completed Date:  2011-10-04     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  9432230     Medline TA:  Cancer Gene Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  489-99     Citation Subset:  IM    
Cancer Research Unit, Research Division, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use
Breast Neoplasms / drug therapy*,  immunology*,  therapy
CD8-Positive T-Lymphocytes / immunology*
Killer Cells, Natural / immunology*
Mice, Inbred C57BL
Mice, Transgenic
Ovalbumin / genetics,  metabolism
Receptor, erbB-2 / genetics,  metabolism*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 9006-59-1/Ovalbumin; EC, erbB-2; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gen...
Next Document:  AUTISM Spectrum Disorders and Suicidality.